Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Stock Information for Arcimoto Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arcimoto Inc.

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine to Present at 36th Annual Roth Conference
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.